Tumor Mutational Burden as a Predictor of Survival With Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2023 Feb 20.
View in:
PubMed
Diagnostic performance of computed tomography features in detecting oropharyngeal squamous cell carcinoma extranodal extension. Eur Radiol. 2023 Jan 31.
View in:
PubMed
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study. Ann Oncol. 2023 03; 34(3):262-274.
View in:
PubMed
Biomarkers predictive of response to pembrolizumab in head and neck cancer. Cancer Med. 2022 Dec 07.
View in:
PubMed
Association of Pretreatment Circulating Tumor Tissue-Modified Viral HPV DNA With Clinicopathologic Factors in HPV-Positive Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2022 12 01; 148(12):1120-1130.
View in:
PubMed
Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors. Cancer Cell. 2022 10 10; 40(10):1161-1172.e5.
View in:
PubMed
[Analysis of anorectal manometry data in central and peripheral neurological deseases: Review of the literature]. Prog Urol. 2022 Dec; 32(17):1505-1518.
View in:
PubMed
[Is pressure transmission quality during cystometry dependent on the type of effort?] Prog Urol. 2022 Sep; 32(11):763-768.
View in:
PubMed
Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 08; 20(8):925-951.
View in:
PubMed
Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy. Cell. 2022 08 04; 185(16):2918-2935.e29.
View in:
PubMed
De novo nocturia: A red flag for coronary heart disease patients. Prog Urol. 2022 Sep; 32(11):756-762.
View in:
PubMed
Aqua: A new questionnaire assessing anticholinergic side effects in neurogenic population (Aqua: Anticholinergic side effects questionnaire). Prog Urol. 2022 Sep; 32(11):751-755.
View in:
PubMed
Clinical trial data of Anti-PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal Carcinoma: A review. Cancer Treat Rev. 2022 Sep; 109:102428.
View in:
PubMed
Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study. Ann Oncol. 2022 08; 33(8):836-844.
View in:
PubMed
[An initial lack of knowledge of the perineal anatomy does not influence the learning of intermittent self-catheterization in women]. Prog Urol. 2022 Sep; 32(11):744-750.
View in:
PubMed
Head and neck cancer: high-end technology is no guarantee of high-quality care - Authors' reply. Lancet. 2022 06 04; 399(10341):2102.
View in:
PubMed
[Prioritization of risk situations in neuro-urology: Guidelines based on the Delphi method from Association française d'urologie (AFU), Association francophone internationale des groupes d'animation de la paraplégie (AFIGAP), Groupe de neuro-urologie de langue française (GENULF), Société française de médecine physique et de réadaptation (SOFMER) and Société interdisciplinaire francophone d'urodynamique et de pelvi-périnéologie (SIFUD-PP)]. Prog Urol. 2022 Sep; 32(10):635-655.
View in:
PubMed
Association between radiation dose to organs at risk and acute patient reported outcome during radiation treatment for head and neck cancers. Head Neck. 2022 06; 44(6):1442-1452.
View in:
PubMed
Fecal incontinence subtype assessment (FI-SA): A new tool to distinguish among subtypes of fecal incontinence in a neurogenic population. Clin Res Hepatol Gastroenterol. 2022 05; 46(5):101900.
View in:
PubMed
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141. Oncologist. 2022 03 04; 27(2):e194-e198.
View in:
PubMed
NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022. J Natl Compr Canc Netw. 2022 03; 20(3):224-234.
View in:
PubMed
Use of Fluoro-[18F]-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity Cancers. JAMA Otolaryngol Head Neck Surg. 2022 Mar 01; 148(3):268-276.
View in:
PubMed
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. J Immunother Cancer. 2022 02; 10(2).
View in:
PubMed
Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders. J Immunother Cancer. 2022 01; 10(1).
View in:
PubMed
Oligometastatic adenoid cystic carcinoma: Correlating tumor burden and time to treatment with outcomes. Head Neck. 2022 03; 44(3):722-734.
View in:
PubMed
Exposed bone in patients with head and neck cancer treated with radiation therapy: An analysis of the Observational Study of Dental Outcomes in Head and Neck Cancer Patients (OraRad). Cancer. 2022 02 01; 128(3):487-496.
View in:
PubMed
Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 02 01; 28(3):468-478.
View in:
PubMed
Comprehensive Immunoprofiling of High-Risk Oral Proliferative and Localized Leukoplakia. Cancer Res Commun. 2021 Oct; 1(1):30-40.
View in:
PubMed
Head and neck cancer. Lancet. 2021 12 18; 398(10318):2289-2299.
View in:
PubMed
Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study. Lung Cancer. 2021 10; 160:78-83.
View in:
PubMed
A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma. Oral Oncol. 2021 08; 119:105366.
View in:
PubMed
CDKN2A Alterations and Response to Immunotherapy in Solid Tumors. Clin Cancer Res. 2021 07 15; 27(14):4025-4035.
View in:
PubMed
Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis. Clin Transl Oncol. 2021 Sep; 23(9):1885-1904.
View in:
PubMed
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2021 04; 22(4):450-462.
View in:
PubMed
Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations. J Clin Oncol. 2021 06 10; 39(17):1856-1864.
View in:
PubMed
[Neurological complications of coitus: Review of literature]. Prog Urol. 2021 Jun; 31(7):392-405.
View in:
PubMed
Clinical Decision-making About Neoadjuvant Nivolumab Plus Ipilimumab-Reply. JAMA Oncol. 2021 02 01; 7(2):309-310.
View in:
PubMed
Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. J Clin Oncol. 2021 03 01; 39(7):840-859.
View in:
PubMed
Correction: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. Clin Cancer Res. 2021 Jan 01; 27(1):357.
View in:
PubMed
Reply to "Keynote 48: Is it really for everyone?" Oral Oncol. 2021 04; 115:105108.
View in:
PubMed
Hospitalization rates and 30-day all-cause mortality among head and neck cancer patients and survivors with COVID-19. Oral Oncol. 2021 01; 112:105087.
View in:
PubMed
Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study. Cancer Cell. 2020 Dec 14; 38(6):769-770.
View in:
PubMed
Circulating tumor cell analysis in locally advanced and metastatic squamous cell carcinoma of the head and neck. Laryngoscope Investig Otolaryngol. 2020 Dec; 5(6):1063-1069.
View in:
PubMed
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. JAMA Oncol. 2020 10 01; 6(10):1563-1570.
View in:
PubMed
Patient reported outcomes in patients with head and neck cancer treated with concurrent chemoradiation with weekly versus bolus cisplatin. Head Neck. 2020 12; 42(12):3670-3677.
View in:
PubMed
A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. Int J Radiat Oncol Biol Phys. 2021 01 01; 109(1):134-144.
View in:
PubMed
Multifocal adult rhabdomyoma of the head and neck: case report and systematic review of the literature. Int J Oral Maxillofac Surg. 2021 Mar; 50(3):327-334.
View in:
PubMed
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. Clin Cancer Res. 2020 10 01; 26(19):5140-5152.
View in:
PubMed
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 07; 18(7):873-898.
View in:
PubMed
Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial. J Clin Oncol. 2020 08 20; 38(24):2773-2781.
View in:
PubMed
Keynote 48: Is it really for everyone? Oral Oncol. 2020 06; 105:104762.
View in:
PubMed
Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. Cancer Immunol Res. 2020 08; 8(8):1075-1084.
View in:
PubMed
The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers. Oncologist. 2020 07; 25(7):598-608.
View in:
PubMed
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. Ann Oncol. 2020 07; 31(7):942-950.
View in:
PubMed
Long-term outcomes and clinicogenomic correlates in recurrent, metastatic adenoid cystic carcinoma. Oral Oncol. 2020 07; 106:104690.
View in:
PubMed
Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2020 06; 105:104676.
View in:
PubMed
Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States. J Med Econ. 2020 May; 23(5):442-447.
View in:
PubMed
Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case series. Oral Dis. 2020 Mar; 26(2):325-333.
View in:
PubMed
Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy. Ann Oncol. 2012 Sep; 23(9):2391-2398.
View in:
PubMed
An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients. JNCI Cancer Spectr. 2020 Apr; 4(2):pkz094.
View in:
PubMed
Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma. Eur J Cancer. 2019 12; 123:138-145.
View in:
PubMed
[Sexual dysfunctions after traumatic brain injury: Systematic review of the literature]. Prog Urol. 2019 Sep; 29(11):529-543.
View in:
PubMed
Best Practice in Systemic Therapy for Head and Neck Squamous Cell Carcinoma. Front Oncol. 2019; 9:815.
View in:
PubMed
Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial. Oral Oncol. 2019 10; 97:82-91.
View in:
PubMed
Evaluating the Utility and Prevalence of HPV Biomarkers in Oral Rinses and Serology for HPV-related Oropharyngeal Cancer. Cancer Prev Res (Phila). 2019 10; 12(10):689-700.
View in:
PubMed
Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial. JAMA Oncol. 2019 Aug 01; 5(8):1170-1180.
View in:
PubMed
Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States. Cancer Epidemiol Biomarkers Prev. 2019 10; 28(10):1660-1667.
View in:
PubMed
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. Cancer. 2019 09 15; 125(18):3208-3218.
View in:
PubMed
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. Clin Cancer Res. 2019 09 01; 25(17):5221-5230.
View in:
PubMed
Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer. Oral Oncol. 2019 08; 95:120-126.
View in:
PubMed
A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck. Int J Radiat Oncol Biol Phys. 2019 09 01; 105(1):132-139.
View in:
PubMed
Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma. Eur J Cancer. 2019 05; 113:1-9.
View in:
PubMed
Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma. Ann Oncol. 2019 03 01; 30(3):471-477.
View in:
PubMed
Everolimus in Anaplastic Thyroid Cancer: A Case Series. Front Oncol. 2019; 9:106.
View in:
PubMed
IMRT-based treatment of unknown primary malignancy of the head and neck: Outcomes and improved toxicity with decreased mucosal dose and larynx sparing. Head Neck. 2019 04; 41(4):959-966.
View in:
PubMed
[Use of botulinum toxin A in pelvic floor dysfunctions in the elderly: A review]. Prog Urol. 2019 Mar; 29(4):216-225.
View in:
PubMed
NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018. J Natl Compr Canc Netw. 2018 12; 16(12):1429-1440.
View in:
PubMed
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial. JAMA Oncol. 2018 11 01; 4(11):1583-1588.
View in:
PubMed
Toward a Personalized Approach in the Treatment of Salivary Ductal Carcinoma. J Natl Compr Canc Netw. 2018 10; 16(10):1269-1270.
View in:
PubMed
Improved outcomes in PI3K-pathway-altered metastatic HPV oropharyngeal cancer. JCI Insight. 2018 09 06; 3(17).
View in:
PubMed
Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer. Ann Oncol. 2018 09 01; 29(9):1980-1986.
View in:
PubMed
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet. 2018 09; 50(9):1271-1281.
View in:
PubMed
Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma. Oral Oncol. 2018 10; 85:29-34.
View in:
PubMed
Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2018 09 01; 102(1):137-145.
View in:
PubMed
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer. 2018 07; 119(2):153-159.
View in:
PubMed
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. Oncologist. 2018 09; 23(9):1079-1082.
View in:
PubMed
Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol. 2018 07; 82:83-90.
View in:
PubMed
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018. J Natl Compr Canc Netw. 2018 05; 16(5):479-490.
View in:
PubMed
Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions. Ann Oncol. 2018 05 01; 29(5):1130-1140.
View in:
PubMed
Management of treatment-related toxicities in advanced medullary thyroid cancer. Cancer Treat Rev. 2018 May; 66:64-73.
View in:
PubMed
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018 06; 81:45-51.
View in:
PubMed
[Cardiovascular adverse effects of antimuscarinics used in the treatment of overactive bladder in the elderly : A review]. Prog Urol. 2018 Jun; 28(7):361-369.
View in:
PubMed
Integrated genomic characterization of oral carcinomas in post-hematopoietic stem cell transplantation survivors. Oral Oncol. 2018 06; 81:1-9.
View in:
PubMed
Frameshift events predict anti-PD-1/L1 response in head and neck cancer. JCI Insight. 2018 02 22; 3(4).
View in:
PubMed
Cabozantinib in Patients with Advanced Merkel Cell Carcinoma. Oncologist. 2018 07; 23(7):814-821.
View in:
PubMed
Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study. Clin Cancer Res. 2018 04 01; 24(7):1546-1553.
View in:
PubMed
The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. Oncologist. 2017 11; 22(11):1413.
View in:
PubMed
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. Ann Oncol. 2017 Oct 01; 28(10):2526-2532.
View in:
PubMed
Patient-oriented toxicity endpoints after head and neck reirradiation with intensity modulated radiation therapy. Oral Oncol. 2017 10; 73:160-165.
View in:
PubMed
Comparative Analysis of MicroRNA Expression among Benign and Malignant Tongue Tissue and Plasma of Patients with Tongue Cancer. Front Oncol. 2017; 7:191.
View in:
PubMed
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 2017 08; 18(8):1104-1115.
View in:
PubMed
NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017. J Natl Compr Canc Netw. 2017 06; 15(6):761-770.
View in:
PubMed
Management of elderly patients with locoregionally confined head and neck cancer. Lancet Oncol. 2017 05; 18(5):e274-e283.
View in:
PubMed
[Post-orgasmic illness syndrome]. Prog Urol. 2017 Jun; 27(7):446-448.
View in:
PubMed
Highlights in Head and Neck Cancer. JAMA Oncol. 2017 04 01; 3(4):441-442.
View in:
PubMed
Advances in Collaborative Practice for Patients With Head and Neck Cancers. J Adv Pract Oncol. 2017 Apr; 8(3):261-265.
View in:
PubMed
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. J Clin Oncol. 2017 May 10; 35(14):1542-1549.
View in:
PubMed
The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. Oncologist. 2017 03; 22(3):343-350.
View in:
PubMed
Human papillomavirus (HPV) 16 antibodies at diagnosis of HPV-related oropharyngeal cancer and antibody trajectories after treatment. Oral Oncol. 2017 04; 67:77-82.
View in:
PubMed
Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2017 04; 67:61-69.
View in:
PubMed
Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. Endocrine. 2017 Apr; 56(1):121-128.
View in:
PubMed
Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma. Cancer Biomark. 2017; 19(2):129-136.
View in:
PubMed
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016 11 10; 375(19):1856-1867.
View in:
PubMed
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. J Clin Oncol. 2016 11 10; 34(32):3838-3845.
View in:
PubMed
Antiangiogenic agents in head and neck squamous cell carcinoma: Tired of going solo. Cancer. 2016 12 01; 122(23):3592-3595.
View in:
PubMed
Acupuncture for Chemoradiation Therapy-Related Dysphagia in Head and Neck Cancer: A Pilot Randomized Sham-Controlled Trial. Oncologist. 2016 12; 21(12):1522-1529.
View in:
PubMed
Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck. Cancer. 2016 Dec 01; 122(23):3632-3640.
View in:
PubMed
Patterns of failure after reirradiation with intensity-modulated radiation therapy and the competing risk of out-of-field recurrences. Oral Oncol. 2016 10; 61:19-26.
View in:
PubMed
Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. Br J Cancer. 2016 07 12; 115(2):252-60.
View in:
PubMed
Mouthwash use and cancer of the head and neck: a pooled analysis from the International Head and Neck Cancer Epidemiology Consortium. Eur J Cancer Prev. 2016 07; 25(4):344-8.
View in:
PubMed
Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients. J Immunother Cancer. 2016; 4:32.
View in:
PubMed
Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. Cancer Immunol Res. 2016 08; 4(8):679-87.
View in:
PubMed
The role of oral hygiene in head and neck cancer: results from International Head and Neck Cancer Epidemiology (INHANCE) consortium. Ann Oncol. 2016 08; 27(8):1619-25.
View in:
PubMed
Population-based validation of the recursive partitioning analysis-based staging system for oropharyngeal cancer. Head Neck. 2016 10; 38(10):1530-8.
View in:
PubMed
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial. Ann Oncol. 2016 08; 27(8):1585-93.
View in:
PubMed
Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2016 06 15; 22(12):2939-49.
View in:
PubMed
Human papillomavirus and induction chemotherapy versus concurrent chemoradiotherapy in locally advanced oropharyngeal cancer: The Dana Farber Experience. Head Neck. 2016 04; 38 Suppl 1:E1618-24.
View in:
PubMed
The evolution of an integrated ultrasound curriculum (iUSC) for medical students: 9-year experience. Crit Ultrasound J. 2015 Dec; 7(1):18.
View in:
PubMed
Sequential and Concurrent Chemoradiation: State of the Art. Hematol Oncol Clin North Am. 2015 Dec; 29(6):1061-74.
View in:
PubMed
Prognostic Implication of Persistent Human Papillomavirus Type 16 DNA Detection in Oral Rinses for Human Papillomavirus-Related Oropharyngeal Carcinoma. JAMA Oncol. 2015 Oct; 1(7):907-15.
View in:
PubMed
Optimizing Tobacco Cessation Resource Awareness Among Patients and Providers. J Oncol Pract. 2016 Jan; 12(1):e77-82.
View in:
PubMed
Anaplastic Thyroid Carcinoma, Version 2.2015. J Natl Compr Canc Netw. 2015 Sep; 13(9):1140-50.
View in:
PubMed
Head and Neck Cancers, Version 1.2015. J Natl Compr Canc Netw. 2015 Jul; 13(7):847-55; quiz 856.
View in:
PubMed
Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. J Clin Oncol. 2015 Jun 20; 33(18_suppl):LBA6008.
View in:
PubMed
Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study. Oral Oncol. 2015 Aug; 51(8):751-8.
View in:
PubMed
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol. 2015 May; 16(5):583-94.
View in:
PubMed
Ensuring head and neck oncology patients receive recommended pretreatment dental evaluations. J Oncol Pract. 2015 Mar; 11(2):151-4.
View in:
PubMed
Genomic analysis of metastatic cutaneous squamous cell carcinoma. Clin Cancer Res. 2015 Mar 15; 21(6):1447-56.
View in:
PubMed
Barriers to clinical trial recruitment in head and neck cancer. Oral Oncol. 2015 Mar; 51(3):203-11.
View in:
PubMed
Marital status and head and neck cancer outcomes. Cancer. 2015 Apr 15; 121(8):1273-8.
View in:
PubMed
Thyroid carcinoma, version 2.2014. J Natl Compr Canc Netw. 2014 Dec; 12(12):1671-80; quiz 1680.
View in:
PubMed
Human papillomavirus-associated oropharynx cancer (HPV-OPC): treatment options. Curr Treat Options Oncol. 2014 Dec; 15(4):595-610.
View in:
PubMed
Ensuring head and neck oncology patients receive recommended pretreatment dental evaluations. J Clin Oncol. 2014 Oct 20; 32(30_suppl):100.
View in:
PubMed
Optimizing smoking cessation resource awareness among patients and providers. J Clin Oncol. 2014 Oct 20; 32(30_suppl):85.
View in:
PubMed
Characterization of HPV and host genome interactions in primary head and neck cancers. Proc Natl Acad Sci U S A. 2014 Oct 28; 111(43):15544-9.
View in:
PubMed
Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014 Oct 09; 371(15):1426-33.
View in:
PubMed
Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2014 Oct; 12(10):1454-87.
View in:
PubMed
[Bacterial ecology and resistance to antibiotics in patients with neurogenic overactive bladder treated with intravesical botulinum toxin injections]. Prog Urol. 2014 Oct; 24(12):744-9.
View in:
PubMed
New frontiers and treatment paradigms for thyroid carcinoma. Clin Adv Hematol Oncol. 2014 Jul; 12(7 Suppl 14):3-21; quiz 22.
View in:
PubMed
Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy. BMC Cancer. 2014 Jun 28; 14:473.
View in:
PubMed
Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners. J Clin Oncol. 2014 Aug 10; 32(23):2408-15.
View in:
PubMed
Human papillomavirus-associated adenocarcinoma of the palatine tonsil--reply. Hum Pathol. 2014 Apr; 45(4):895.
View in:
PubMed
Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. Cancer. 2013 Dec 15; 119(24):4268-76.
View in:
PubMed
Targeted therapies for squamous cell carcinoma of the head and neck: current knowledge and future directions. Cancer Treat Rev. 2014 Apr; 40(3):390-404.
View in:
PubMed
How to incorporate new tyrosine kinase inhibitors in the treatment of patients with medullary thyroid cancer. J Clin Oncol. 2013 Oct 10; 31(29):3618-20.
View in:
PubMed
Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013 Aug; 11(8):917-23.
View in:
PubMed
Larynx preservation: a debate worth preserving. J Clin Oncol. 2013 Sep 01; 31(25):3170.
View in:
PubMed
Success of endoscopic pharyngoesophageal dilation after head and neck cancer treatment. Laryngoscope. 2013 Dec; 123(12):3066-73.
View in:
PubMed
Oral HPV infection in HPV-positive oropharyngeal cancer cases and their spouses. J Clin Oncol. 2013 Jun 20; 31(18_suppl):CRA6031.
View in:
PubMed
Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res. 2013 Aug 15; 73(16):5195-205.
View in:
PubMed
A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN). Oral Oncol. 2013 Aug; 49(8):835-41.
View in:
PubMed
New developments in thyroid cancer. J Natl Compr Canc Netw. 2013 May; 11(5 Suppl):705-7.
View in:
PubMed
Organ preservation for adenoid cystic carcinoma of the larynx. Oncologist. 2013; 18(5):579-83.
View in:
PubMed
Human papillomavirus-associated adenocarcinoma of the base of the tongue. Hum Pathol. 2013 Aug; 44(8):1516-23.
View in:
PubMed
Induction chemotherapy for locoregionally advanced head and neck cancer: past, present, future? Oncologist. 2013; 18(3):288-93.
View in:
PubMed
Trastuzumab for the treatment of salivary duct carcinoma. Oncologist. 2013; 18(3):294-300.
View in:
PubMed
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013 Mar; 14(3):257-64.
View in:
PubMed
Locally advanced head and neck cancer. Am Soc Clin Oncol Educ Book. 2013; 237-44.
View in:
PubMed
Vandetanib for the treatment of medullary thyroid cancer. Clin Cancer Res. 2013 Feb 01; 19(3):524-9.
View in:
PubMed
Metastatic human papillomavirus-positive nasopharyngeal carcinoma with an unusual pattern of aggressive hematogenous spread. J Clin Oncol. 2012 Nov 10; 30(32):e321-3.
View in:
PubMed
Biomarkers of HPV in head and neck squamous cell carcinoma. Cancer Res. 2012 Oct 01; 72(19):5004-13.
View in:
PubMed
Metabolic syndrome (MetS) in Lebanese patients with schizophrenia receiving atypical antipsychotic drugs. Asian J Psychiatr. 2013 Feb; 6(1):88-9.
View in:
PubMed
Genetic polymorphisms modulate the folate metabolism of Brazilian individuals with Down syndrome. Mol Biol Rep. 2012 Oct; 39(10):9277-84.
View in:
PubMed
Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature. Oral Oncol. 2012 Nov; 48(11):1085-9.
View in:
PubMed
Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. Oral Oncol. 2012 Dec; 48(12):1281-8.
View in:
PubMed
Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy. Ann Oncol. 2012 Sep; 23(9):2391-2398.
View in:
PubMed
Acupuncture for dysphagia after chemoradiation in head and neck cancer: rationale and design of a randomized, sham-controlled trial. Contemp Clin Trials. 2012 Jul; 33(4):700-11.
View in:
PubMed
Mucosal melanoma of the head and neck. J Natl Compr Canc Netw. 2012 Mar; 10(3):320-38.
View in:
PubMed
Factors associated with smoking abstinence among smokers and recent-quitters with lung and head and neck cancer. Lung Cancer. 2012 May; 76(2):144-9.
View in:
PubMed
Swallowing function following postchemoradiotherapy neck dissection: review of findings and analysis of contributing factors. Otolaryngol Head Neck Surg. 2011 Sep; 145(3):428-34.
View in:
PubMed
Novel biomarker panel predicts prognosis in human papillomavirus-negative oropharyngeal cancer: an analysis of the TAX 324 trial. Cancer. 2012 Apr 01; 118(7):1811-7.
View in:
PubMed
Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer. Br J Cancer. 2011 Jun 07; 104(12):1896-905.
View in:
PubMed
Head and neck cancers. J Natl Compr Canc Netw. 2011 Jun 01; 9(6):596-650.
View in:
PubMed
Effect of yoga on QOL, cortisol rhythym, and HRV for women with breast cancer undergoing radiotherapy. J Clin Oncol. 2011 May 20; 29(15_suppl):9009.
View in:
PubMed
Treatment of oral cavity squamous cell carcinoma with adjuvant or definitive intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e215-22.
View in:
PubMed
Oral epithelial dysplasia and squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes. Bone Marrow Transplant. 2011 Jun; 46(6):884-91.
View in:
PubMed
EHT0202 in Alzheimer's disease: a 3-month, randomized, placebo-controlled, double-blind study. Curr Alzheimer Res. 2011 Mar; 8(2):203-12.
View in:
PubMed
Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol. 2011 May; 22(5):1071-1077.
View in:
PubMed
Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324. Int J Radiat Oncol Biol Phys. 2011 Dec 01; 81(5):e813-8.
View in:
PubMed
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol. 2011 Feb; 12(2):153-9.
View in:
PubMed
Patient-reported receipt of and interest in smoking-cessation interventions after a diagnosis of cancer. Cancer. 2011 Jul 01; 117(13):2961-9.
View in:
PubMed
Patient-reported receipt of and interest in smoking-cessation interventions after a diagnosis of cancer. Cancer. 2011 Jan 10.
View in:
PubMed
Efficacy and toxicity of chemoradiotherapy using intensity-modulated radiotherapy for unknown primary of head and neck. Int J Radiat Oncol Biol Phys. 2011 Aug 01; 80(5):1405-11.
View in:
PubMed
Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):308-14.
View in:
PubMed
Thyroid carcinoma. J Natl Compr Canc Netw. 2010 Nov; 8(11):1228-74.
View in:
PubMed
Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer. Cancer. 2010 Oct 15; 116(20):4761-8.
View in:
PubMed
Utilizing computed tomography as a road map for designing selective and superselective neck dissection after chemoradiotherapy. Otolaryngol Head Neck Surg. 2010 Sep; 143(3):367-74.
View in:
PubMed
Acupuncture for dysphagia after chemoradiation therapy in head and neck cancer: a case series report. Integr Cancer Ther. 2010 Sep; 9(3):284-90.
View in:
PubMed
Polymerase chain reaction detection of HPV in squamous carcinoma of the oropharynx. Am J Clin Pathol. 2010 Jul; 134(1):36-41.
View in:
PubMed
Medullary carcinoma. J Natl Compr Canc Netw. 2010 May; 8(5):512-30.
View in:
PubMed
Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2010 Jun; 95(6):2664-71.
View in:
PubMed
Combined antegrade and retrograde esophageal dilation for head and neck cancer-related complete esophageal stenosis. Laryngoscope. 2010 Feb; 120(2):261-6.
View in:
PubMed
beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial. J Clin Oncol. 2009 Dec 20; 27(36):6222-8.
View in:
PubMed
Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann Oncol. 2010 Feb; 21(2):342-347.
View in:
PubMed
Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer. 2009 Oct 01; 115(19):4514-23.
View in:
PubMed
Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 2009 Sep 20; 27(27):4448-53.
View in:
PubMed
Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res (Phila). 2009 Sep; 2(9):776-81.
View in:
PubMed
Induction chemotherapy in head and neck cancer. J Clin Oncol. 2009 Aug 10; 27(23):e52-3; author reply e54.
View in:
PubMed
Re: Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009 Aug 19; 101(16):1157-8; author reply 1158.
View in:
PubMed
Epstein-Barr virus (EBV)-specific immunotherapy in nasopharygneal carcinoma (NPC). J Clin Oncol. 2009 May 20; 27(15_suppl):6025.
View in:
PubMed
Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009 Nov 01; 75(3):725-33.
View in:
PubMed
Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol. 2009 May; 20(5):921-7.
View in:
PubMed
Clinical Practice Guidance For Radiotherapy Planning Following Induction Chemotherapy In Locoregionally Advanced Head And Neck Cancer
. International Journal of Radiation Oncology, Biology,
Physics
. 2009; In Press.
Seeking alternative biological therapies. The future of targeted molecular treatment. Oral Oncology-In Press. 2008.
Induction chemotherapy in locally advanced head and neck cancer: a new standard of care? Hematol Oncol Clin North Am. 2008 Dec; 22(6):1155-63, viii.
View in:
PubMed
Head and Neck Cancer Update: Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care.(Online CME). 2008.
Seeking alternative biological therapies: the future of targeted molecular treatment. Oral Oncol. 2009 Apr-May; 45(4-5):447-53.
View in:
PubMed
Recurrent Squamous Cell Carcinoma of the Tongue. 2008.
Sequential Therapy for the Locally Advanced Larynx and Hypopharynx Cancer Subgroup in TAX 324: Survival, Surgery, and Organ Preservation. Annals of Oncology-In Press. 2008.
A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions. Cancer Prev Res (Phila). 2008 Oct; 1(5):339-48.
View in:
PubMed
Recent advances in head and neck cancer. N Engl J Med. 2008 Sep 11; 359(11):1143-54.
View in:
PubMed
Radiation treatment breaks and ulcerative mucositis in head and neck cancer. Oncologist. 2008 Aug; 13(8):886-98.
View in:
PubMed
Trends in Head and Neck Cancer. The American Journal of Hematology/Oncology. 2008; 7(8):323-324.
Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008 Nov 15; 72(4):1110-8.
View in:
PubMed
Phase I study of panitumumab + chemoradiotherapy (CRT) for head and neck cancer (HNC). J Clin Oncol. 2008 May 20; 26(15_suppl):6007.
View in:
PubMed
A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):6024.
View in:
PubMed
Sequential therapy for locally advanced larynx and hypopharynx cancer: Subgroup analysis from the TAX 324 Study. J Clin Oncol. 2008 May 20; 26(15_suppl):6031.
View in:
PubMed
Cetuximab added to docetaxel, cisplatin, 5-fluorouracil Induction chemotherapy (C-TPF) in patients with newly diagnosed locally advanced head and neck cancer: A phase I study. J Clin Oncol. 2008 May 20; 26(15_suppl):6001.
View in:
PubMed
Sequential therapy for locally advanced larynx and hypopharynx cancer: Subgroup analysis from the TAX 324 Study. J Clin Oncol 26: 2008 (May 20 suppl; abstr 6031). 2008.
A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 26: 2008 (May 20 suppl; abstr 6024). 2008.
Cetuximab added to docetaxel, cisplatin, 5-fluorouracil Induction chemotherapy (C-TPF) in patients with newly diagnosed locally advanced head and neck cancer: A phase I study. J Clin Oncol 26: 2008 (May 20 suppl; abstr 6001). 2008.
Phase I study of panitumumab + chemoradiotherapy (CRT) for head and neck cancer (HNC). J Clin Oncol 26: 2008 (May 20 suppl; abstr 6007). 2008.
Human Papillomavirus Infection and Oropharynx Cancer. Published in "News from S.P.O.H.N.C" Support for People with Oral and Head and Neck Cancer. 2008.
A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid. 2008 Mar; 18(3):317-23.
View in:
PubMed
Multidisciplinary approach to cancer treatment: focus on head and neck cancer. Dent Clin North Am. 2008 Jan; 52(1):1-17, vii.
View in:
PubMed
The MTR A2756G polymorphism is associated with an increase of plasma homocysteine concentration in Brazilian individuals with Down syndrome. Braz J Med Biol Res. 2008 Jan; 41(1):34-40.
View in:
PubMed
HPV16 transmission between a couple with HPV-related head and neck cancer. Oral Oncol. 2008 Aug; 44(8):812-5.
View in:
PubMed
Effect of folate, vitamin B6, and vitamin B12 intake and MTHFR C677T polymorphism on homocysteine concentrations of renal transplant recipients. Transplant Proc. 2007 Dec; 39(10):3163-5.
View in:
PubMed
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007 Oct 25; 357(17):1705-15.
View in:
PubMed
Novel agents for the treatment of mucositis. J Support Oncol. 2007 Oct; 5(9 Suppl 4):33-9.
View in:
PubMed
Open-label, long-term safety study of cevimeline in the treatment of postirradiation xerostomia. Int J Radiat Oncol Biol Phys. 2007 Dec 01; 69(5):1369-76.
View in:
PubMed
Human Papillomavirus Infection and Oropharyngeal Cancer.(Online CME). 2007.
Trends in Head and Neck Cancer. The American Journal of Hematology/Oncology. 2007; Vol 6. No 4(4):187-188.
Behavior of oral squamous cell carcinoma in subjects with prior lichen planus. Otolaryngol Head Neck Surg. 2007 Mar; 136(3):401-4.
View in:
PubMed
Retropharyngeal nodes in hypopharynx cancer on positron emission tomography. J Clin Oncol. 2007 Feb 10; 25(5):599-601.
View in:
PubMed
Oral Mucous Membrane Macrobiotica in Health and Oral Squamous Cell Carcinoma. Grand Rounds in Oral-Systemic Medicine. 2007; 2(1):12-8.
Translational studies of depsipeptide, a histone deacetylase (HDAC) inhibitor in patients with head and neck cancer [abstract]. Proc Am Assoc Cancer Res 48: A3524
. 2007.
Phase I study of panitumumab, chemotherapy, and intensity-modulated radiotherapy (IMRT) for head and neck cancer (HNC): Early results.
. Proc Am Soc Clin Oncol 1/1/2007; 25: Abstr #6083. 2007.
Swallowing function after IMRT and chemotherapy for head and neck cancer. Proc Am Soc Clin Oncol 1/1/2007; 25: Abstr #6046
. Proc Am Soc Clin Oncol 1/1/2007; 25: Abstr #6046. 2007.
Head and Neck Carcinoma: American College of Physicians (ACP) On-line publication, Physicians Information and Education Resource (PIER).
. Online. 2007.
Combination of angiotensin-converting enzyme and methylenetetrahydrofolate reductase gene polymorphisms as determinant risk factors for chronic allograft dysfunction. Transplant Proc. 2007 Jan-Feb; 39(1):78-80.
View in:
PubMed
Clinical and translational studies of depsipeptide, a histone deacetylase inhibitor, in patients with squamous cell carcinoma of the head and neck: New York Cancer Consortium Trial P6335 [abstract]. Proc Am Soc Clin Oncol 1/1/2007; 25: A6065
. 2007.
Changing Paradigms in the Treatment of Squamous Cell Carcinoma of the Head and Neck. (Online CME). 2006.
[Pilomatricoma or calcifying epithelioma of Malherbe. A pediatric review of 89 cases]. Ann Chir Plast Esthet. 2007 Feb; 52(1):39-42.
View in:
PubMed
Emerging drugs for head and neck cancer. Expert Opin Emerg Drugs. 2006 Sep; 11(3):461-7.
View in:
PubMed
Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated with regimen-related toxicities in patients being treated for head and neck cancers. Oral Oncol. 2007 Mar; 43(3):289-300.
View in:
PubMed
PET/CT imaging in patients with suspected recurrence of pancreatic cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):14137.
View in:
PubMed
Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2006 Jun; 132(6):678-81.
View in:
PubMed
Dysphagia after sequential chemoradiation therapy for advanced head and neck cancer. Otolaryngol Head Neck Surg. 2006 Jun; 134(6):916-22.
View in:
PubMed
Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys. 2006 Jul 15; 65(4):1036-44.
View in:
PubMed
Examining the need for neck dissection in the era of chemoradiation therapy for advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2006 May; 132(5):526-31.
View in:
PubMed
Chemoradiotherapy for adenoid cystic carcinoma: preliminary results of an organ sparing approach. Am J Clin Oncol. 2006 Apr; 29(2):153-7.
View in:
PubMed
Current and future directions in the treatment of squamous cell carcinoma of the head and neck: multidisciplinary symposium on head and neck cancer. Expert Opin Ther Targets. 2006 Apr; 10(2):333-6.
View in:
PubMed
Integrating novel agents in the curative treatment of head and neck cancer. Exp. Rev, Anti. Ther. 2006; 6(2):157-9.
Integrating novel agents into the curative treatment of head and neck cancer. Expert Rev Anticancer Ther. 2006 Feb; 6(2):157-9.
View in:
PubMed
Cetuximab in squamous cell carcinoma of the head and neck. Am. J. Onc. Rev. 2006; 1(1).
Use of Peripheral Blood Monocytes (PBM) to Define Changes in Gene Expression Associated with Amifostine Treatment And Their Association With Oral Mucositis (OM) In Patients Being Treated With Chemoradiotherapy For Squamous Cell Carcinoma of the Head and Neck (SCCHN). American Society of Therapeutic Radiation Oncology (ASTRO) Meeting. 2006.
A phase III trial of TPF vs. PF Induction Chemotherapy Followed by chemoradiotherapy in Locally Advanced SCCHN. Special Session ASCO. 2006.
The Evolution of induction chemotherapy and sequential therapy for locally advanced squamous cell cancer of the head and neck. ASCO Educational Book. 2006; 346-52.
A Phase III Open-Label, Long-Term Safety Study of Cevimeline Hydrochloride in Patients with Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region. ASTRO Meeting. 2006.
Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2005 Oct 01; 23(28):6976-81.
View in:
PubMed
Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer. Am J Clin Oncol. 2005 Aug; 28(4):371-8.
View in:
PubMed
Pilot study of celecoxib in oral premalignant lesions (OPLs): Preliminary results. J Clin Oncol. 2005 Jun; 23(16_suppl):1025.
View in:
PubMed
Rate of complete pathological responses (pCR) to docetaxel/cisplatin/5-fluorouracil (TPF) induction chemotherapy in patients with newly diagnosed, locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 2005 Jun; 23(16_suppl):5511.
View in:
PubMed
Chemoradiation-induced cell loss in human submandibular glands. Laryngoscope. 2005 Jun; 115(6):958-64.
View in:
PubMed
Long term survival with adjuvant carboplatin, paclitaxel, and radiation therapy in anaplastic thyroid cancer. Am J Clin Oncol. 2005 Feb; 28(1):104.
View in:
PubMed
Concomitant Chemoradiation Using Weekly Carboplatin/Paclitaxel With or Without Daily Subcutaneous Amifostine in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck. ASTRO meeting 2005. Denver , CO. IJROBP supplement. 2005; 63, 2:2229.
Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck. Oral Oncol. 2005 Jan; 41(1):70-6.
View in:
PubMed
The Evolution of Induction Chemotherapy in Locally Advanced Squamous Cell Cancer of the Head and Neck: The New Paradigm of Sequential Therapy. Head and Neck Cancer, Adelstein, D (ed). 2005; 171-86.
Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin Oncol. 2004 Dec; 31(6):778-85.
View in:
PubMed
Endoscopic management of hypopharyngeal stenosis after organ sparing therapy for head and neck cancer. Laryngoscope. 2004 Nov; 114(11):1924-31.
View in:
PubMed
Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head Neck. 2004 Oct; 26(10):890-6.
View in:
PubMed
A phase I/II study of docetaxel (D) and concomitant boost radiation (CBR) for patients with squamous cell cancer of the head and neck (SCCHN) following induction chemotherapy (IC). J Clin Oncol. 2004 Jul 15; 22(14_suppl):5548.
View in:
PubMed
Phase I study of gefitinib plus celecoxib in patients with metastatic and/or locally recurrent squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 2004 Jul 15; 22(14_suppl):5540.
View in:
PubMed
Interleukin-8 (IL-8) serum levels and squamous cell cancer of the head and neck (SCCHN). J Clin Oncol. 2004 Jul 15; 22(14_suppl):9716.
View in:
PubMed
Organ preservation for patients treated with induction chemotherapy (IC) followed by radiation therapy (RT) or chemoradiation (CRT) for advanced stage squamous cell carcinoma of the larynx (SCCL). J Clin Oncol. 2004 Jul 15; 22(14_suppl):5600.
View in:
PubMed
Interleukin-8 (IL-8) Serum Levels and Squamous Cell Cancer of the Head and Neck (SCCHN). Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition)(July 15 Supplement). 2004; 22 No14S:9716.
A phase I/II study of docetaxel (D) and concomitant boost radiation (CBR) for patients with squamous cell cancer of the head and neck (SCCHN) following induction chemotherapy (IC). Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition)(July 15 Supplement). 2004; 22, No 14S:5548.
Phase I study of gefitinib plus celecoxib in patients with metastatic and/or locally recurrent squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition) (July 15 Supplement). 2004; 22, No 14S:5540.
A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor. Clin Cancer Res. 2004 Jul 15; 10(14):4680-7.
View in:
PubMed
Organ preservation for patients treated with induction chemotherapy (IC) followed by radiation therapy (RT) or chemoradiation (CRT) for advanced stage squamous cell carcinoma of the larynx (SCCL). Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition)(July 15 Supplement). 2004; 22, No 14S:5600.
The Role of Epidermal Growth Factor Receptor Inhibitors In Head And Neck Cancer. Am. J. Onc. Rev. 2004; 3(7).
RE: Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer. N. Engl. J. Med. 2004; 350(10):1051-2.
Nonsurgical treatment of laryngeal cancer. N Engl J Med. 2004 Mar 04; 350(10):1049-53; author reply 1049-53.
View in:
PubMed
Respiratory mechanics and pleural remodelling in pleurodesis induced by barium sulphate. Respir Physiol Neurobiol. 2004 Feb 25; 139(3):271-80.
View in:
PubMed
HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res. 2004 Feb 01; 10(3):944-6.
View in:
PubMed
RE: Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: randomized, double blind, placebo-controlled trial. Lancet. 2004; 363(9402):79-80.
Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet. 2004 Jan 03; 363(9402):79-80; author reply 81-2.
View in:
PubMed
A method for rating charts to identify and classify patients with medically unexplained symptoms. Psychother Psychosom. 2004 Jan-Feb; 73(1):36-42.
View in:
PubMed
Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. Semin Oncol. 2003 Dec; 30(6 Suppl 18):84-8.
View in:
PubMed
Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol. 2003 Oct; 39(7):724-7.
View in:
PubMed
Spontaneous long-term remission in a patient with premature ovarian failure. Endocr Pract. 2003 Sep-Oct; 9(5):380-3.
View in:
PubMed
Phase II study of docetaxel and topotecan combination chemotherapy in patients with advanced head and neck cancer. Cancer Chemother Pharmacol. 2003 Oct; 52(4):303-6.
View in:
PubMed
Integration of chemotherapy in the curative treatment of locally advanced head and neck cancer. Expert Rev Anticancer Ther. 2003 Jun; 3(3):331-8.
View in:
PubMed
Progress and perspectives in chemoprevention of head and neck cancer. Expert Rev Anticancer Ther. 2003 Jun; 3(3):339-55.
View in:
PubMed
Palliative Chemotherapy in Patients With Salivary Gland Neoplasms: Review of The Literature and Preliminary Reports of Two Recently Performed Phase II Studies With Single Agents Herceptin And Gemcitabine. Clinical Advances in Hematology & Oncology. 2003; (1):226-8.
Palliative chemotherapy in patients with salivary gland neoplasms and preliminary reports of 2 recent phase II studies with trastuzumab and gemcitabine. Clin Adv Hematol Oncol. 2003 Apr; 1(4):226-8.
View in:
PubMed
Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer. 2003 Mar 15; 97(6):1589; author reply 1590.
View in:
PubMed
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Cancer. 2003 Jan 15; 97(2):412-8.
View in:
PubMed
A Phase II Study of E7070 in Patients with Metastatic, Recurrent, or Refractory Head and Neck Squamous Cell Carcinoma (HNSCC): Clinical activity and post-treatment modulation of Rb phosphorylation. Proc. Am. Soc. Clin. Oncol. (abstr 800) (Poster discussion session). 2003; 22:200.
Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment. Oncologist. 2003; 8(1):35-44.
View in:
PubMed
49 year old male with locally advanced squamous cell carcinoma of the head and neck: the case for sequential chemoradiotherapy programs. Clin Adv in Hematol Oncol. 2003; 1(1):58-61.
A 49-year-old male with locally advanced squamous cell carcinoma of the head and neck: the case for sequential chemoradiotherapy. Clin Adv Hematol Oncol. 2003 Jan; 1(1):58-60; discussion 61-2.
View in:
PubMed
Docetaxel, Cisplatin and 5-fluouracil (TPF) based induction chemotherapy for locally advanced head and neck cancer: long term survival and salvage. (ASCO Proc). 2002; 21:960.
A Phase I/II Trial Of Concurrent Docetaxel And Concomitant Boost Radiation Therapy For Patients With Squamous Cell Cancer Of The Head And Neck Following Induction Chemotherapy: A Sequential Combined Modality Approach. (ASCO Proc). 2002; 21:2561.
Immunoguided lymph node dissection in colorectal cancer: a new challenge? World J Surg. 2001 Dec; 25(12):1495-8; discussion 1499.
View in:
PubMed
Regression and clonally distinct recurrence of human immunodeficiency virus related Burkitt-like lymphoma during antiretroviral therapy. Leuk Lymphoma. 2001 Sep-Oct; 42(5):1125-31.
View in:
PubMed
Self-assembly of mesoscopically ordered chromatic polydiacetylene/silica nanocomposites. Nature. 2001 Apr 19; 410(6831):913-7.
View in:
PubMed
Segmental resection for recurrent carcinoma of the esophagus. Isr Med Assoc J. 2001 Mar; 3(3):228-9.
View in:
PubMed
Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck. Cancer. 2001 Feb 01; 91(3):548-54.
View in:
PubMed
Effects of intravenous gamma immunoglobulins treatment on severe peritonitis in rats. Int J Surg Investig. 2001; 2(6):433-42.
View in:
PubMed
Antineoplastic Drug Development. The Chemotherapy Source Book, Perry MC (ed). 2001.
Superselective Intraarterial Cisplatin In Patients With Squamous Cell Carcinoma Of The Head And Neck: University Of Maryland Experience. (ASCO Proc). 2001; 20:2562.
A Phase II Trial of Taxotere, Topotecan Combination Chemotherapy in Patients with Recurrent, Metastatic SCC of the Head and Neck. (AACR). 2001.
Restriction landmark genomic scanning of mouse liver tumors for gene amplification: overexpression of cyclin A2. Biochem Biophys Res Commun. 2000 Jul 21; 274(1):188-96.
View in:
PubMed
The effects of somatostatin and octreotide on experimental and human acute pancreatitis. J Lab Clin Med. 2000 Feb; 135(2):112-21.
View in:
PubMed
Identification of lymph node metastases in recurrent colorectal cancer. Recent Results Cancer Res. 2000; 157:281-92.
View in:
PubMed
Pretreatment Hemoglobin (Hgb) Is Associated With Response to Chemoradiation Therapy (CRT) in Patients with Advanced, Unresectable Squamous Cell Carcinoma of the Head and Neck (SCCHN). (ASCO Proc)(Poster discussion session). 2000; 19:1646.
[Photodynamic therapy for dysphagia due to esophageal carcinoma]. Harefuah. 1999 Nov 15; 137(10):441-4, 512.
View in:
PubMed
Erythema nodosum after smoke inhalation-induced bronchiolitis obliterans organizing pneumonia. Crit Care Med. 1999 Jun; 27(6):1214-6.
View in:
PubMed
Continuous intravenous octreotide treatment for acute experimental pancreatitis. Digestion. 1999 Mar-Apr; 60(2):125-31.
View in:
PubMed
Anchoring the diaphragm after blunt trauma. Injury. 1999 Jan; 30(1):57-8.
View in:
PubMed
Delayed Use of Granulocyte Colony-Stimulating Factor Following Autologous Peripheral Blood Stem Cell Transplantation Does Not Affect Engraftment or Hospital Stay. Blood. 1999; 10(Supp 1):4821.
Single-injection gamma probe-guided sentinel lymph node detection in 40 melanomatous lymphadenectomies. Ann Plast Surg. 1998 Oct; 41(4):397-401.
View in:
PubMed
In vitro and in vivo effects of photodynamic therapy on murine malignant melanoma. Ann Surg Oncol. 1998 Apr-May; 5(3):241-7.
View in:
PubMed
Localization of monoclonal antibody CC49 in colonic metastasis from renal cell carcinoma. Eur J Surg Oncol. 1998 Apr; 24(2):149-51.
View in:
PubMed
Genomic imprinting and Igf2 influence liver tumorigenesis and loss of heterozygosity in SV40 T antigen transgenic mice. Cancer Res. 1997 Oct 15; 57(20):4615-23.
View in:
PubMed
Impact of early orchidopexy on testicular growth. Br J Urol. 1997 Aug; 80(2):334-5.
View in:
PubMed
Preoperative pulmonary function tests do not predict outcome after coronary artery bypass. Conn Med. 1997 Jun; 61(6):327-32.
View in:
PubMed
Endometriosis in abdominal scars: a diagnostic pitfall. Am Surg. 1996 Dec; 62(12):1042-4.
View in:
PubMed
[Hand burns in children. Retrospective study of 137 cases from 1973-1982 representing 177 hands]. Chir Pediatr. 1984; 25(1):43-7.
View in:
PubMed